Darwin Global Management
Latest statistics and disclosures from Darwin Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PCVX, NUVL, KROS, BHVN, ALPN, and represent 73.25% of Darwin Global Management's stock portfolio.
- Added to shares of these 10 stocks: PCVX (+$148M), NUVL (+$104M), BHVN (+$81M), ALPN (+$79M), BEAM (+$70M), APGE (+$55M), KROS (+$25M), XNCR (+$25M), SYRE (+$18M), ELEV (+$12M).
- Started 9 new stock positions in TRML, ALPN, BHVN, APGE, XNCR, ELEV, SYRE, BEAM, MRK.
- Reduced shares in these 5 stocks: Ambrx Biopharma (-$238M), TGTX (-$69M), MLTX (-$63M), CYTK (-$50M), SWTX (-$7.0M).
- Sold out of its positions in CYTK, MLTX, Ambrx Biopharma, SWTX, TGTX.
- Darwin Global Management was a net buyer of stock by $210M.
- Darwin Global Management has $751M in assets under management (AUM), dropping by 47.44%.
- Central Index Key (CIK): 0001839209
Tip: Access up to 7 years of quarterly data
Positions held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Darwin Global Management
Darwin Global Management holds 12 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Vaxcyte (PCVX) | 25.0 | $188M | +374% | 2.8M | 68.31 |
|
| Nuvalent Inc-a (NUVL) | 14.4 | $108M | +2390% | 1.4M | 75.09 |
|
| Keros Therapeutics (KROS) | 12.7 | $95M | +35% | 1.4M | 66.20 |
|
| Biohaven (BHVN) | 10.8 | $81M | NEW | 1.5M | 54.69 |
|
| Alpine Immune Sciences (ALPN) | 10.5 | $79M | NEW | 2.0M | 39.64 |
|
| Beam Therapeutics (BEAM) | 9.3 | $70M | NEW | 2.1M | 33.04 |
|
| Apogee Therapeutics (APGE) | 7.4 | $55M | NEW | 832k | 66.45 |
|
| Xencor (XNCR) | 3.3 | $25M | NEW | 1.1M | 22.13 |
|
| Spyre Therapeutics Com New (SYRE) | 2.4 | $18M | NEW | 473k | 37.93 |
|
| Elevation Oncology (ELEV) | 1.6 | $12M | NEW | 2.3M | 5.13 |
|
| Tourmaline Bio (TRML) | 1.4 | $11M | NEW | 465k | 22.90 |
|
| Merck & Co (MRK) | 1.4 | $11M | NEW | 80k | 131.95 |
|
Past Filings by Darwin Global Management
SEC 13F filings are viewable for Darwin Global Management going back to 2020
- Darwin Global Management 2024 Q1 filed May 15, 2024
- Darwin Global Management 2023 Q4 filed Feb. 14, 2024
- Darwin Global Management 2023 Q3 filed Nov. 14, 2023
- Darwin Global Management 2023 Q2 filed Aug. 14, 2023
- Darwin Global Management 2023 Q1 filed May 15, 2023
- Darwin Global Management 2022 Q4 filed Feb. 14, 2023
- Darwin Global Management 2022 Q3 filed Nov. 14, 2022
- Darwin Global Management 2022 Q2 filed Aug. 15, 2022
- Darwin Global Management 2022 Q1 filed May 16, 2022
- Darwin Global Management 2021 Q4 filed Feb. 14, 2022
- Darwin Global Management 2021 Q3 filed Nov. 15, 2021
- Darwin Global Management 2021 Q2 filed Aug. 16, 2021
- Darwin Global Management 2021 Q1 filed May 17, 2021
- Darwin Global Management 2020 Q4 filed Feb. 16, 2021